June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Ranibizumab Therapy for Neovascular AMD in eyes with good vision (>6/12): visual outcomes and cost-effectiveness based on real world outcomes of 92,976 treatment episodes
Author Affiliations & Notes
  • Adnan Tufail
    Ophthalmology, Moorfields Eye Hospital, London, United Kingdom
  • Cecilia S Lee
    University of Washington, Seattle, WA
  • Aaron Lee
    University of British Columbia, Vancouver, BC, Canada
  • Catherine A Egan
    Ophthalmology, Moorfields Eye Hospital, London, United Kingdom
  • Dawn A Sim
    Ophthalmology, Moorfields Eye Hospital, London, United Kingdom
  • Robert Johnston
    Cheltenham General Hospital, Cheltenham, United Kingdom
  • Thomas Butt
    Insititute of Ophthalmology, UCL, London, United Kingdom
  • Footnotes
    Commercial Relationships Adnan Tufail, allergan (C), Bayer (C), Notal (F), Novartis (F), Roche (C); Cecilia Lee, None; Aaron Lee, Notal Vision (F); Catherine Egan, Novartis (F); Dawn Sim, None; Robert Johnston, Medisoft Ltd (F), Novartis (F); Thomas Butt, Notal Vision (F)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 5365. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Adnan Tufail, Cecilia S Lee, Aaron Lee, Catherine A Egan, Dawn A Sim, Robert Johnston, Thomas Butt, ; Ranibizumab Therapy for Neovascular AMD in eyes with good vision (>6/12): visual outcomes and cost-effectiveness based on real world outcomes of 92,976 treatment episodes. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):5365.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Outcomes of eyes with good vision (>6/12, >70 ETDRS letters) were not evaluated in the pivotal trials for ranibizumab. We evaluated the effectiveness, and cost-effectiveness of treatment with ranibizumab in patients with neovascular AMD (nAMD) with good starting visual acuity using real-world outcomes data.

Methods: Anonymised structured data were collected from 14 centers using an EMR system. The primary outcome was the mean VA at year 1, 2, and 3. Secondary measures included the number of clinic visits and injections. A patient-level health economic state transition model based on levels of visual acuity in the better seeing eye was constructed to simulate the costs and consequences of treating nAMD patients. In the model two treatment approaches were compared: immediate intervention with ranibizumab PRN (on detection of nAMD) or delayed intervention (wait until vision fell to 6/12 before beginning treatment).

Results: The study included 12,951 treatment-naive eyes of 11,135 patients receiving 92,976 ranibizumab treatments. A total of 754 patients had baseline VA better than 6/12 and at least one-year of follow up. Mean VA of first treated eyes with baseline VA > 6/12 at year 1, 2, 3 were 6/10, 6/12, 6/15, respectively and those with baseline VA 6/12 to > 6/24 were 6/15, 6/17, 6/20, respectively (p-values <0.001 for comparing differences between 6/12 and 6/12-6/24 groups). For the second eyes with baseline VA > 6/12, mean VA at year 1, 2, 3 were 6/9, 6/9, 6/10, and those with baseline VA 6/12 to > 6/24 were 6/15, 6/15, 6/27, respectively (p-values <0.001-0.005). There was no significant difference in average number of clinic visits or injections between those with VA better or worse than 6/12. Over a two-year time horizon, based on 10,000 Monte Carlo simulations, the early treatment arm accumulated 1.59 QALYs and £8,469.79 cost. The delayed treatment arm accumulated 1.35 QALYs and £7,460.21 cost. The ICER was £4,251.60.

Conclusions: Eyes with baseline VA > 6/12 maintained better mean VA than the eyes with baseline VA 6/12 to > 6/24 at all time points for at least 2 years. An economic model based on real-world data is likely to be a realistic reflection of the health gains and resource use of ranibizumab for nAMD. Initiating treatment immediately in eyes with good vision with ranibizumab is a cost effective strategy.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×